Status:

COMPLETED

Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies

Lead Sponsor:

Stiefel, a GSK Company

Collaborating Sponsors:

GlaxoSmithKline

Conditions:

Psoriasis

Eligibility:

All Genders

12+ years

Phase:

PHASE3

Brief Summary

The purpose of the study is to demonstrate the safety and efficacy of U0267 in subjects with plaque-type psoriasis.

Eligibility Criteria

Inclusion

  • Male or female subjects at least 12 years old and in good general health.
  • Mild to moderate plaque-type psoriasis

Exclusion

  • Known allergy or other adverse reaction to calcipotriene or other vitamin D analogs; or to any component of the investigational formulations
  • History of hypercalcemia or of vitamin D toxicity.
  • Diagnosis of generalized pustular or erythrodermic exfoliative psoriasis.
  • Other serious skin disorder or any chronic medical condition that is not well controlled.
  • Use of non-biologic systemic anti-psoriatic therapy or biologic therapy within four weeks of enrollment.
  • Use of topical therapies that have a known beneficial effect on psoriasis, within 2 weeks of enrollment.
  • Systemic medications for other medical conditions that are known to affect psoriasis within the past four weeks of enrollment.
  • Use of any investigational therapy within 4 weeks of enrollment.
  • Pregnant women, women who are breast feeding, or sexually active women of child bearing potential who are not practicing an acceptable method of birth control.

Key Trial Info

Start Date :

March 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2008

Estimated Enrollment :

336 Patients enrolled

Trial Details

Trial ID

NCT00688519

Start Date

March 1 2008

End Date

December 1 2008

Last Update

January 2 2017

Active Locations (13)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (13 locations)

1

Therapeutics Clinical Research Center, Inc.

San Diego, California, United States, 92123

2

Cherry Creek Research, Inc.

Denver, Colorado, United States, 80209

3

Florida Academic Dermatology Centers

Miami, Florida, United States, 33136

4

FXM Research

Miami, Florida, United States, 33175